Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTFK8YB)

• DTT Name: Bacterial DNA topoisomerase 4A (Bact parC) DTT Info
• Gene Name: Bact parC

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prulifloxacin	DMOK965	Urinary tract infection	GC08	Approved	[1]

5 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pazufloxacin	DMHXTAQ	Conjunctivitis	9A60	Phase 3	[2]
Sitafloxacin	DMTV5XC	Escherichia coli infection	1A03	Phase 2/3	[3]
JNJ-32729463	DMQD1GN	Community-acquired pneumonia	CA40.Z	Phase 2	[4]
TNP-2092	DM8DZKI	Skin and skin-structure infection	1F28-1G0Z	Phase 2	[5]
VB 1953	DM0YWQ4	Acne vulgaris	ED80	Phase 2	[6]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A-62824	DMJ6IMZ	Discovery agent	N.A.	Investigative	[7]

References

• [1] Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41.
• [2] Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7.
• [3] Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104.
• [4] Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.
• [5] Clinical pipeline report, company report or official report of TenNor Therapeutics.
• [6] Clinical pipeline report, company report or official report of Vyome Therapeutics.
• [7] Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent anti... Bioorg Med Chem Lett. 2006 Mar 1;16(5):1272-6.